ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) Continues To Slip

Posted by Chris Bell January 2, 2014 0 Comment 1540 views


ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) the evolving bio tech firm attempting to develop new cures for various forms of human cancer had a forgettable start to 2014 at the markets yesterday. Its stock suffered a big sell out at the hands of investors leading to a 5.6 percent decrease in its market value in one day of trading. These sell out reversed the nearly 6.3 percent increase the stock had posted in its valuation during trading in the last week of December.

Stock Witnessed A See Saw

The sell-off in the stock of ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) yesterday comes as a surprise to many of its long term investors since just on December 27, the drug firm had announced forward looking updates to its phase i clinical trials for its target cancer vaccine  code named ICT-121 which is being positioned to treat recurring brain cancer.

CEO Speak

Adding his commentary to the public announcement of the initiation of trails for this potential drug, ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) CEO Andrew Gengos has been quoted as saying, “The start of this ICT-121 trial signifies an expansion of our commitment to developing treatments for patients with GBM, and to the continued advancement of our pipeline of dendritic cell-based immunotherapeutic cancer vaccines. In 2014 we expect to have three active cancer vaccine clinical programs, led by ICT-107 in newly diagnosed GBM and including ICT-140 in ovarian cancer and ICT-121.”

About The Drug Maker

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) is  an $52.81 million market capped small cap drug maker which has its HQ in Calabasas. This firm has been classified as a clinical-stage biotechnology company. It has been engaged to in the design and development of treatments for various forms of cancer. It currently boasts of a big pipeline of target drugs which are in various phases of phase 11 clinical trials.



About Chris Bell

Chris Bell is an investing reporter for GDP Insider. Chris covers financial markets and Wall Street, concentrating on developments affecting individual investors and their portfolios. Chris is also over consumer reporter and covers a wide variety of issues ranging from housing to immigration to urban poverty. Chris graduated from the University of Scranton with a degree in Communication and Philosophy. Chris's diligent investigations earned him the honor of being named "Best Reporter" once by the Headliners Foundation of Texas and once by the Houston Press Club.

View all post by Chris Bell Visit author's website

Write Your Comment